Showing 1 - 10 results of 10 for search 'Si Shi', query time: 0.02s Refine Results
  1. 1
    Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1)

    Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of... by Jin Xu, Si Shi, Jie Hua, Miaoyan Wei, Xianjun Yu

    Published 2019-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Intrauterine Contraception Use among Women Receiving Post-Abortion Care in Guangzhou, China: A Cross-Sectional Study

    Intrauterine Contraception Use among Women Receiving Post-Abortion Care in Guangzhou, China: A Cross-Sectional Study by Xuehuan Feng, Si Shi, Jinzhi Liu, Jing Zhou, Ribo Xiong, Yan Liu

    Published 2022-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis

    Cancer type-specific adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis by Xuhui Tong, Rong Tang, Jin Xu, Wei Wang, Qiong Du, Si Shi, Xianjun Yu

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Gonadotropin dose selection for repeat IVF cycles in POSEIDON Groups 1 and 2

    Gonadotropin dose selection for repeat IVF cycles in POSEIDON Groups 1 and 2 by Hao Wei, JinLiang Duan, SiShi Wang, BaoPing Zhu, HaiLing Jiang

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Interventional therapies for chronic heart failure: An overview of recent developments

    Interventional therapies for chronic heart failure: An overview of recent developments by Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    The novel GSDMD inhibitor GI‐Y2 exerts antipyroptotic effects to reduce atherosclerosis

    The novel GSDMD inhibitor GI‐Y2 exerts antipyroptotic effects to reduce atherosclerosis by Xiaoxi Fan, Zhenfeng Cheng, Ruiyin Shao, Keke Ye, Xudong Chen, Xueli Cai, Shanshan Dai, Zhixuan Tang, Si Shi, Wenyuan Zheng, Weijian Huang, Jibo Han, Bozhi Ye

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial

    Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung can... by Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Feng Ye, Xing Zhang, Baorui Liu, Dongmei Ji, Yanqiao Zhang, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma

    Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma

    Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma by Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu

    Published 2024-09-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers

    Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers by Zhihao Lu, Mingfei Geng, Yongtao Han, Jianzhong Cao, Jun Wang, Tianshu Liu, Xianglin Yuan, Xue Meng, Yanqiao Zhang, Rong Zhao, Lixin Wan, Enxiao Li, Wenran Wang, Zhijie Li, Danfeng Shi, Jing Qian, Si Shi, Fengshi Dong, Lin Shen

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: